Allogeneic hematopoietic cell transplant (HCT) in patients (pts) >= 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR.
Publication
, Conference
Schiller, GJ; Ritchie, EK; Sayar, H; Lancet, JE; Craig, MD; Vey, N; Strickland, SA; Erba, HP; Pigneux, A; Horst, H-A; Recher, C; Klimek, VM ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2015
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2015
Volume
33
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Schiller, G. J., Ritchie, E. K., Sayar, H., Lancet, J. E., Craig, M. D., Vey, N., … Ravandi, F. (2015). Allogeneic hematopoietic cell transplant (HCT) in patients (pts) >= 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 33). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
Schiller, Gary J., Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael D. Craig, Norbert Vey, Stephen Anthony Strickland, et al. “Allogeneic hematopoietic cell transplant (HCT) in patients (pts) >= 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
Schiller GJ, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, et al. Allogeneic hematopoietic cell transplant (HCT) in patients (pts) >= 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.
Schiller, Gary J., et al. “Allogeneic hematopoietic cell transplant (HCT) in patients (pts) >= 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR.” JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 15, AMER SOC CLINICAL ONCOLOGY, 2015.
Schiller GJ, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Erba HP, Pigneux A, Horst H-A, Recher C, Klimek VM, Odenike O, Craig AR, Ward R, Smith J, Kantarjian HM, Stuart RK, Ravandi F. Allogeneic hematopoietic cell transplant (HCT) in patients (pts) >= 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2015
Volume
33
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences